Motivations to share genomic health information

What motivates the sharing of consumer-generated genomic information?

Rachele M Hendricks-Sturrup1 and Christine Y Lu1

Abstract
Genomic medicine is an emerging practice that followed the completion of the Human Genome Project and that considers genomic information about an individual in the provision of their clinical care. Large and start-up direct-to-consumer genetic testing companies like Ancestry, 23andMe, Luna DNA, and Nebula Genomics have capitalized on findings from the Human Genome Project by offering genetic health testing services to consumers without a clinical intermediary. Genomic medicine is thus further propelled by unprecedented supply and demand market forces driven by direct-to-consumer genetic testing companies. As government entities like the National Human Genome Research Institute question how genomics can be implemented into routine medical practice to prevent disease and improve the health of all members of a diverse community, we believe that stakeholders must first examine how and scenarios in which stakeholders can become motivated to share or receive genomic information. In this commentary, we discuss consumers’ three scenarios: satisfying personal curiosity, providing a social good, and receiving a financial return. We examine these motivations based on recent events and current avenues through which have engaged or can engage in genomic data sharing via private, secure (e.g., centralized genomic databases and decentralized platforms like blockchain) and public, unsecure platforms (e.g., open platforms that are publicly available online). By examining these scenarios, we can likely determine how various stakeholders, such as consumers, might prefer to extract value from genomic information and how privacy preferences among those stakeholders might vary depending on how they seek to use or share genomic information. From there, one can recommend best practices to promote transparency and uphold privacy standards and expectations among stakeholders engaged in genomic medicine.

Keywords
Genomic medicine, direct-to-consumer genetic testing, privacy, motivation, data sharing

Date received: 5 November 2019; accepted: 20 February 2020

The National Human Genome Research Institute (NHGRI) defines genomic medicine as a “medical discipline that involves using genomic information (also referred to as genomic data) about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use.”1 Genomic medicine emerged following the completion of the Human Genome Project, given the project’s overarching objective to “advance our understanding of biology and disease and to improve health.”2 Several studies have been completed or are underway to determine specific gene variants that cause or increase the likelihood of developing various diseases in demographically diverse populations.

Capitalizing on these research findings are direct-to-consumer genetic testing (DTC-GT) companies that, without a clinical intermediary, offer consumers’ genomic information and summary reports that describe how the consumers’ DNA might influence their health. As leading DTC-GT companies like Ancestry and 23andMe continue to create and introduce new health products, sometimes with regulatory authorization, genomic medicine is further accelerated by supply and demand market forces.3–5 Furthermore, consumers can download and share their genomic information and reports directly with their health care providers and families and other interested third parties (e.g., researchers and health product developers). The clinical validity and utility of these tests, however, remain debated by the scientific and medical community. In addition, DTC-GT for health-related

1Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, MA, USA

Corresponding author: Rachele Hendricks-Sturrup, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, 401 Park Drive, Boston, MA 02215, USA. Email: rachele_hendricks-sturrup@harvardpilgrim.org
purposes contributes to increased burdens placed on health care systems and providers, as DTC-GT consumers often seek medical advice for interpreting and acting on the data findings.6

In their latest vision statement, the NHGRI questioned how genomics can be implemented into routine medical practice to prevent disease and improve the health of all members of a diverse community.7 Specifically, the NHGRI asked, “how do we make sure genomic information is available and useful for all?” Given that DTC-GT testing companies are making genomic information available and useful to individuals and entities at unprecedented levels, we examine three scenarios in which individuals can become motivated to garner and exchange their genomic information beyond their initial interface with DTC-GT companies and across various platforms that offer various incentives. Understanding motivations to share genomic information within and across these three scenarios is important to elucidate privacy expectations, preferences, and trade-offs within those scenarios. Having this understanding would be especially useful for policymakers and other stakeholders or data optimists who are responsible for upholding consumer privacy and have an interest in maximizing the social benefits of sharing DTC-GT data. Moreover, these scenarios can be used as reference points to create practical guidance or tools that can be used to uphold consumer privacy needs and expectations.

**Why is genomic information shared and used?**

Consumers are increasingly engaged in genomic testing to learn about or predict their health, ancestry, and other personal health factors (e.g. amenability to weight loss through specific dieting) and can access genomic testing without a healthcare intermediary and at any time via DTC-GT companies and newly emerging preventive genomics clinics.8 Growing levels of DTC-GT consumer engagement combined with the rapid growth of genomic medicine suggest that consumers are either motivated or inspired to generate, use, and share their raw genomic information when the information can be leveraged in ways that serve consumers’ health needs and goals, values, curiosity, and/or beliefs (e.g. determine genetic health risks, whether or not based on geographic ancestry, or identifying biological family members). Industry, public health practitioners, and health care providers are also motivated to use and share genomic information, particularly when genomic information can be aggregated or combined with phenotypic data, health survey data, and data generated in “real-world” settings (e.g. geographic/location data, consumer wearable data, etc.) to reveal meaningful insights about the combined effects of genetics, behavior, and the environment. Insights gleaned based on evidence generated from such data might be valuable for patients, consumers, and other stakeholders who might ultimately benefit from such discoveries.

Here, we discuss three factors that motivate stakeholders to generate and share genomic information: to satisfy personal curiosity, to provide a social good, and to receive a return on investing or contributing their genomic data. We examine these motivations based on recent events and current avenues through which individuals have engaged or can engage in genomic data sharing via private, secure (e.g. centralized genomic databases and de-centralized platforms like blockchain) and public, unsecure platforms (e.g. open platforms that are publicly available online). By examining the extent to which stakeholders have developed or engaged in these platforms, we can examine and discuss how stakeholders become motivated to engage in genomic information sharing activities.

**Satisfy personal curiosity**

Millions of individuals engage in DTC-GT to satisfy their personal curiosity about their health and geographic ancestry. In April 2019, it was estimated, based on information taken from websites of three leading DTC-GT companies (23&Me, Ancestry, and FamilyTreeDNA), that over 26 million genomic records exist for DTC-GT consumers across those three companies. This is despite public concerns about how DTC-GT companies use, sell, and/or share consumers’ genomic information and despite the fact that most, but not all, DTC-GT companies have privacy policies that incorporate elements of transparency around their data practices.9–11 Beyond finding out about their genetic ancestry and health-related predispositions, DTC-GT consumers also share their genomic information directly in public databases like GEDMatch to find biological relatives.9 The privacy risks to openly sharing genomic information in public forums continue to reveal themselves over time, affecting both individuals who share such information and their biological family members, as seen in the recent Golden State Killer cases.9 Thus, it is possible that some DTC-GT consumers either lack salient concerns about privacy or believe the benefits to learning about their geographic ancestry and genomic health risks outweigh privacy risks.10

**Contribute to social good**

Thousands of individuals are motivated to share or donate their genomic information, de-identified or otherwise, to serve the greater or social good. Publicly available platforms like Open Humans and the Harvard Personal Genome Project (PGP) appeal to individuals who wish to openly share their identifiable genomic information for the purpose of advancing science and medicine (the “greater good”) and under the notion that genomic information privacy and the true de-identification of genomic information are either impossible or an illusion.12,13 For instance, the PGP has nearly 6,000 project participants who shared their personal genomic and trait data in a free and open manner to serve the “greater
Regarding the California Consumer Privacy Act of 2018 determining the value of consumer-generated data.

Nied by the need for nondiscrimination protections related to genomic health risks. Genomic information can be housed in the public ClinVar database to possibly determine individuals’ genomes against public variant data. This newly emerging practice, however, is accompanied by the need for nondiscrimination protections related to the NIH discovering new ways to understand health and disease.

Haeusermann et al. conducted one of the first global surveys (n = 550) to determine individual impetus to openly share their DTC-GT results on a public platform called openSNP and without any institutional oversight and determine individual attitudes on issues of privacy. On openSNP, users can upload their genomic data using either pseudonyms or their real names and sometimes link their social media profiles to openSNP profiles. Most of the survey respondents came from the United States (60.33%), followed by Canada (5.17%) and the United Kingdom (4.61%), with the remaining coming from other countries that include Australia (3.32%), France (2.21%), Switzerland (2.21%), Russia (2.03%), and Italy (1.48%). At least 79% of the respondents (with variation between men and women up to 89%) felt it relevant or very relevant to share their genomic information to not only learn about themselves, but also contribute to the advancement of medical research. Since then, other studies have found similar results.

Receive a return on data investment

The PGP seemingly refers to the “greater good” as “unimpeded research and other scientific, patient care and commercial purposes worldwide.” Thus, one can assume that the greater good also involves engaging individuals or entities that seek to leverage genomic and trait data in the economy or market. Recent events also show that individuals and entities are being incentivized to generate and exchange genetic information for economic returns like shares in a company or legal tender via distributed ledger or blockchain platforms that are appraised as highly secure, de-centralized, and private. This newly emerging practice, however, is accompanied by the need for nondiscrimination protections related to determining the value of consumer-generated data.

The California Attorney General acknowledged this occurrence in a recent notice of proposed rulemaking action regarding the California Consumer Privacy Act of 2018 (CCPA) and described what business practices constitute as discriminatory when offering financial incentives in exchange for consumer data and provide guidance on how to calculate the value of consumer data when designing financial incentives. To promote transparency around this practice, the CCPA requires that businesses publicly disclose the estimated value of a consumer’s data and the method used to calculate and determine the value of the data. As an example of transparency, in their Security Exchange Commission (SEC) Offering Circular, LunaDNA publicly disclosed their valuation methods to determine the cash value of different types of “Member Data” and the number of shares issued in exchange for the contribution of such Member Data (see Figure 1). LunaDNA is the first blockchain enterprise to offer company shares in exchange for genomic information with SEC approval. Their valuation methods for genomic information exchanged via blockchain are likely adopted by other genomics companies that leverage blockchain and promote consumer ownership over DTC-GT data in the marketplace like Nebula Genomics, EncrypGen, and Zenome.

Understanding stakeholder preferences and expectations

DTC-GT consumers pay to gain insights into what their genomic information means and, upon this, have an option to consent or opt-in to participation in research conducted internally and commercially by DTC-GT companies. Consumers may also consent to DTC-GT companies sharing insights gleaned from consumers’ genetic data with third parties. This consent is likely given, however, after consumers skim terms and conditions that might be lengthy or difficult to understand. Also, there is much variation in transparency or clarity around DTC-GT companies’ data sharing activities internally and with third parties.

Many questions arise about what DTC-GT consumers might expect to learn from their genetics, if they fully consider the potential impact or consequences to their engagement in DTC-GT, and if they consider genomic data sharing as a personal or social investment. For instance, how do DTC-GT genetic test consumers perceive the value of test results that suggest a high risk for a disease with no known cure or treatment? Furthermore, do consumers care about how DTC-GT companies share or leverage consumers’ information when the companies establish business partnerships? Finally, when DTC-GT companies leverage consumers’ genetic data to pursue partnerships with third parties and develop genomics-based products (e.g., pharmacogenomic testing and drugs), what is the likelihood that consumers are able to afford such products? These are important questions to consider when determining DTC-GT consumer preferences and expectations, which are grounded in how those stakeholders perceive the utility of the genomic information they obtain, share, or permit for use.

Illustrating this point is one case (Greenberg v. Miami Childrens Research Institute) in which a physician-researcher isolated and patented the Canavan gene sequence and developed a genetic testing process to detect the gene in patients. Parents of children with Canavan disease, who shared their 

19 Greenberg v. Miami Childrens Research Institute

20 LunaDNA is the first blockchain enterprise to offer company shares in exchange for genomic information with SEC approval.

21 LunaDNA is the first blockchain enterprise to offer company shares in exchange for genomic information with SEC approval.

22 LunaDNA is the first blockchain enterprise to offer company shares in exchange for genomic information with SEC approval.

23 LunaDNA is the first blockchain enterprise to offer company shares in exchange for genomic information with SEC approval.

24 LunaDNA is the first blockchain enterprise to offer company shares in exchange for genomic information with SEC approval.
children’s tissue to support the research, contended that if they had known upfront of the physician-researcher’s intent to commercialize the genomic information through patenting and restrictive licensing, then they would not have shared, or would have kept private, their children’s genomic information. Thus, it is important to better understand variations in privacy preferences or expectations (see Figure 2) and their influences on how stakeholders obtain, share, or permit for use of genomic information. This case also illustrates the role of transparency, as a lack of transparency among key stakeholders can have detrimental consequences long-term.

A systematic literature review conducted by Clayton et al.24 sought to determine concerns about genetic privacy and how these concerns affect individuals’ willingness to accept genetic testing in clinical care and to participate in genomics research. After reviewing 53 studies involving the perspectives of 47,974 participants, they concluded that there is variation in how much individuals want control over the use of their data. They also explained how little attention has focused on understanding how contextual factors like information salience and social forces (e.g. the presence or absence of privacy and nondiscrimination laws and regulations) can influence individual opinions, perceptions, and

| Member Data Provided                                                                 | Shares Issued | Estimated Fair Market Value |
|-------------------------------------------------------------------------------------|---------------|-----------------------------|
| DNA Targeted Genes                                                                  | 10            | $0.70                       |
| Genotyping by DNA Genome-wide Microarray or Sequencing                               | 50            | $3.50                       |
| DNA Exome                                                                           | 150           | $10.50                      |
| DNA Whole Genome                                                                    | 300           | $21.00                      |
| DNA Tumor Targeted Genes                                                            | 10            | $0.70                       |
| DNA Tumor Genome-wide Genotyping                                                    | 50            | $3.50                       |
| DNA Tumor Exome                                                                     | 150           | $10.50                      |
| DNA Tumor Whole Genome                                                              | 300           | $21.00                      |
| DNA Targeted Methylation, including supporting collection information               | 10            | $0.70                       |
| DNA Whole Genome Methylation, including supporting collection information           | 20            | $1.40                       |
| RNA Genome-wide Expression, including supporting collection information             | 10            | $0.70                       |
| RNA Targeted Gene Expression, including supporting collection information           | 20            | $1.40                       |
| RNA Whole Transcriptome, including supporting collection information                | 40            | $2.80                       |
| RNA Tumor Genome-wide Expression                                                    | 10            | $0.70                       |
| RNA Tumor Targeted Gene Expression                                                  | 20            | $1.40                       |
| RNA Tumor Whole Transcriptome                                                       | 40            | $2.80                       |
| Targeted Microbiome, including supporting collection information                     | 20            | $1.40                       |
| Whole Microbiome, including supporting collection information                        | 50            | $3.50                       |
| Health Records - Clinical Reports (ex. Lab results)                                  | 4             | $0.28                       |
| Health Records - Prescription Reports, including supporting collection information   | 10            | $0.70                       |
| PDF of Historical Health Record (per year of reports)                               | 2             | $0.14                       |
| Electronic Survey (per 10 min average completion time)                              | 2             | $0.14                       |
| Personal Fitness Monitor (per 20 days of data)                                      | 2             | $0.14                       |
| Clinically Certified Device (per 20 days of data)                                   | 2             | $0.14                       |
| Nutrition Tracker (per 20 days of data)                                             | 2             | $0.14                       |

**Figure 1.** Aggregate offering price or aggregate sales for Luna DNA, LLC, shares based on the fair value of LunaDNA member data. Source: [https://support.lunadna.com/support/solutions/articles/43000486909-lunadna-sec-offering-circular](https://support.lunadna.com/support/solutions/articles/43000486909-lunadna-sec-offering-circular).

**Figure 2.** Underpinnings to variation in stakeholder privacy preferences and expectations when sharing genomic information.
decisions to share and use genomic information. Thus, more research is needed to understand how the identified, and possibly unidentified, personal, social, and economic factors can intrinsically motivate individuals to engage in genomic information sharing.

Looking forward

Here we highlight several circumstances under which individuals are or can become motivated to share their genomic information: to satisfy personal curiosity, to provide a social good, and to receive financial return. As stated, clearly understanding stakeholders’ motivations across these three scenarios is important in order to elucidate privacy expectations, preferences, and trade-offs within those scenarios. A clear understanding could contribute to the establishment of practical guidance to uphold consumer needs and expectations across these scenarios. Clayton et al. emphasized the importance in determining (1) social practices that make the collection and use of genomic data more trustworthy and (2) circumstances that cause individuals to set aside their concerns about genomic information sharing and engage in genomic information sharing activities. Thus, there is opportunity to engage and promote further research that can closely examine how various stakeholders perceive or value genomic information within and across these three contexts. As examples, further research could inform the development of protective policy and legal frameworks, predictive modeling informed by behavioral economic and/or ethical theories, and the development of new or adapted frameworks that can be used for intervention development and analyses. New or adapted models and frameworks within this scope are would be timely and are needed to inform policymaking at various levels and promote transparency and best practices that could effectively and realistically uphold privacy standards and consumer expectations.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Rachele Hendricks-Sturrup is employed by the Future of Privacy Forum.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Christine Lu is supported in part by an Ebert Career Development Award at Harvard Pilgrim Health Care Institute and Harvard Medical School, and reports contract with the Center for Genomic Medicine, Massachusetts General Hospital outside the submitted work.

ORCID iD

Rachele Hendricks-Sturrup https://orcid.org/0000-0002-3390-2583

References

1. Genomics and Medicine. Genome.gov, https://www.genome.gov/health/Genomics-and-Medicine (accessed 5 November 2019).
2. The Human Genome Project. Genome.gov, https://www.genome.gov/human-genome-project (accessed 5 November 2019).
3. AncestryHealth® DNA Health Testing & Genetic Health Test, https://www.ancestry.com/health (accessed 5 November 2019).
4. Our Health + Ancestry DNA Service – 23andMe, https://www.23andme.com/dna-health-ancestry/?vip=true (accessed 5 November 2019).
5. FDA. FDA authorizes first-direct-to-consumer test for detecting genetic variants that may be associated with medication metabolism, 2019, http://www.fda.gov/news-events/press-announcements/fda-authorizes-first-direct-consumer-test-detecting-genetic-variants-may-be-associated-medication (accessed 5 November 2019).
6. McGuire AL and Burke W. Health system implications of direct-to-consumer personal genome testing. Public Health Genom 2010; 14(1): 53–58.
7. Strategic planning workshop: genomics in medicine & health. Genome.gov, https://www.genome.gov/event-calendar/strategic-planning-workshop-genomics-in-medicine-and-health (accessed 5 November 2019).
8. Preventive Genomics Clinic, https://brighamandwomen.org/medicine/genetics/genetics-and-genomic-medicine/preventive-genomics-clinic (accessed 5 November 2019).
9. Hendricks-Sturrup RM, Prince AER and Lu CY. Direct-to-consumer genetic testing and potential loopholes in protecting consumer privacy and nondiscrimination. JAMA 2019; 321(19): 1869–1870.
10. Hendricks-Sturrup RM and Lu CY. Direct-to-consumer genetic testing data privacy: key concerns and recommendations based on consumer perspectives. J Pers Med 2019; 9(2): 25.
11. Hazel J and Slobogin C. Who knows what, and when? A survey of the privacy policies proffered by U.S. direct-to-consumer genetic testing companies. Rochester, NY: Social Science Research Network. https://papers.ssrn.com/abstract=3165765 (accessed 5 February 2020).
12. Open Humans. About, https://www.openhumans.org/about (accessed 5 November 2019).
13. The Harvard Personal Genome Project (PGP). About, https://pgp.med.harvard.edu/about (accessed 5 November 2019).
14. Open Humans. Statistics, https://www.openhumans.org/statistics/ (accessed 5 November 2019).
15. ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/ (accessed 5 November 2019).
16. Open Humans. Genevieve genome report, https://www.openhumans.org/activity/genevieve-genome-report/ (accessed 5 November 2019).
17. All of Us Research Hub. About, https://www.researchallofus.org/about/ (accessed 5 November 2019).
18. Shabani M. Blockchain-based platforms for genomic data sharing: a de-centralized approach in response to the governance problems. J Am Med Inform Assoc 2019; 26(1): 76–80.
19. California Consumer Privacy Act (CCPA). State of California, Department of Justice, Office of the Attorney General, 2018, https://oag.ca.gov/privacy/ccpa (accessed 5 November 2019).
20. Thompson D. LunaDNA SEC offering circular. Help center, https://support.lunadna.com/support/solutions/articles/43000486909-lunadna-sec-offering-circular (accessed 5 November 2019).
21. ResearchAndMarkets. Global blockchain in genomics market to 2029: advancing precision medicine with blockchain-powered artificial intelligence, https://www.prnewswire.com/news-releases/global-blockchain-in-genomics-market-to-2029-advancing-precision-medicine-with-blockchain-powered-artificial-intelligence-300939691.html (accessed 5 November 2019).
22. Christofides E and O’Doherty K. Company disclosure and consumer perceptions of the privacy implications of direct-to-consumer genetic testing. New Genet Soc 2016; 35(2): 101–123.
23. United States District Court, S.D. Florida, Miami Division. Greenberg v. Miami Children’s Hospital Research Institute. Wests Fed Suppl 2003; 264: 1064–1078.
24. Clayton EW, Halverson CM, Sathe NA, et al. A systematic literature review of individuals’ perspectives on privacy and genetic information in the United States. PLoS One 2018; 13(10): e0204417.